An anti-HER2 antibody–drug conjugate (RC48, DV) in which a humanized anti‑HER2 monoclonal antibody is linked to the microtubule inhibitor monomethyl auristatin E (MMAE); after binding HER2 on tumor cells and internalization, it releases MMAE to disrupt microtubules, causing G2/M arrest and apoptosis with a potential bystander effect.
Anti-HER2 monoclonal antibody linked to the microtubule inhibitor MMAE; after binding HER2 and internalization, the linker is cleaved to release MMAE, which inhibits tubulin polymerization, causing G2/M cell-cycle arrest and apoptosis, with potential bystander killing.
An anti‑HER2 ADC binds HER2 on tumor cells, is internalized, and releases MMAE intracellularly; MMAE inhibits tubulin polymerization, causing G2/M arrest and apoptosis (with possible bystander killing).
Allogeneic, donor-derived gene-modified chimeric antigen receptor T-cell (CAR-T) product targeting mesothelin (MSLN); designed as an off-the-shelf CAR-T therapy that binds MSLN on tumor cells and induces T-cell activation and cytotoxic killing.
Allogeneic, gene-modified T cells expressing a chimeric antigen receptor that binds mesothelin (MSLN) on tumor cells, activating CAR signaling to induce T-cell effector functions and cytotoxic killing (perforin/granzyme release and cytokine secretion) independent of the native TCR.
CAR-T cells bind mesothelin on target cells, triggering T-cell effector functions (perforin/granzyme-mediated lysis and apoptosis, ± Fas–FasL) leading to direct killing.
Nectin-4–directed antibody–drug conjugate targeting PVRL4; binds to Nectin-4 on tumor cells, is internalized, and releases a cytotoxic payload.
Nectin-4 (PVRL4)–targeted IgG1 antibody–drug conjugate. After binding Nectin-4 on tumor cells, the ADC is internalized and a cleavable linker releases a topoisomerase I inhibitor payload, blocking DNA replication and inducing cell cycle arrest and apoptosis in Nectin-4–expressing cells.
The ADC binds Nectin-4 on target cells, is internalized, and releases a cleavable topoisomerase I inhibitor payload that inhibits DNA replication, leading to cell-cycle arrest and apoptosis.
HER2-targeted bispecific monoclonal antibody that binds two distinct HER2 epitopes to inhibit HER2 signaling and potentially enhance antibody-dependent cellular cytotoxicity (ADCC).
Bispecific anti-HER2 monoclonal antibody that binds two non-overlapping HER2 epitopes, inhibits HER2 heterodimerization and downstream signaling, and induces Fc-mediated ADCC to kill HER2-overexpressing tumor cells.
Binds HER2 on tumor cells and engages Fcγ receptor–bearing effector cells (e.g., NK cells) to mediate antibody-dependent cellular cytotoxicity (ADCC), leading to target-cell lysis; also blocks HER2 signaling.
HER2-targeted bispecific monoclonal antibody that binds two distinct HER2 epitopes to inhibit HER2 signaling and potentially enhance antibody-dependent cellular cytotoxicity (ADCC).
Bispecific anti-HER2 monoclonal antibody that binds two non-overlapping HER2 epitopes, inhibits HER2 heterodimerization and downstream signaling, and induces Fc-mediated ADCC to kill HER2-overexpressing tumor cells.
Antibody binds HER2 and recruits FcγR-expressing effector cells to mediate ADCC, killing HER2+ cells; HER2 signaling blockade can also promote apoptosis.